Signant Health

In 2000, clinical data management meant manual data entry, disconnected systems, and weeks of reconciliation. Today, data managers, developers, and clinical research stakeholders are taking advantage of Signant SmartSignals® Marketplace, where our library of APIs connect clinical ecosystems to simplify workflows using: Seamless integrations with EDC, CTMS, RTSM, and eConsent systems Real-time data synchronization eliminating manual reconciliation Standardized APIs that developers can implement in days, not months Comprehensive documentation and monitoring tools Ready for more efficient clinical data management? Explore our API library: https://hubs.li/Q03TvxNc0 #25YearsOfSignant #ClinicalDataManagement #eClinicalInnovation

Regulators like FDA are underlining the importance of patient-reported outcomes (PROs) in early-phase oncology clinical trials. Including PROs in early-phase studies enables comprehensive tolerability characterization and supports optimal dose determination.    Find out how to implement PROs in early phase oncology programs - get our experts' summary of a new PRO methodology that aligns with regulatory guidance: https://hubs.li/Q03T0vXD0  #clinicaltrials #oncology #eCOA  

Recruitment delays putting your drug supply at risk? We see it coming. Generate accurate, proactive plans for mid-study production using our Forecasting & Planning software. Learn more https://hubs.li/Q03T0j6W0   #pharma #supplychain #clinicalsupply

Capturing patient data for respiratory trials doesn't have to be complicated. This IPF (Idiopathic pulmonary fibrosis) success story proves that our ePRO technology can work even for elderly patient populations, especially when paired with thoughtful design, scientific rigor and operations that scale.   Read the case study: https://hubs.ly/Q03SBvVq0 #ClinicalTrials #RespiratoryResearch

Surveys indicate that research sites juggle an average of 20 or more different technology solutions daily for various aspects of trial management and operations. Our ID Portal changes that: One login. All your Signant technologies. Simple access = more time for patients.   Part of our 25-year commitment to clinical innovation: https://hubs.li/Q03Sqv320 #eClinicalInnovation #25YearsofSignant

Selecting the optimal dose in oncology drug development requires a thorough understanding of patient tolerability. The traditional model of relying on physicians alone misses key symptoms and often underestimates side effect severity. Patient-reported outcomes, including adverse events, are a vital input for robust tolerability characterization in early phase, leading to reliable and accurate dose finding.  Get the oncology experts' guide to a novel methodology for capturing comprehensive PRO data with reduced patient burden: https://hubs.li/Q03RwmCs0 #oncology #clinicaltrials #eCOA

When should you start your next production run? With real-time RTSM integration and scenario modeling, our Forecasting & Planning software gives you the answer instantly. No more spreadsheet guesswork. Just confident decisions. https://hubs.li/Q03Rwms50 #pharma #supplychain #clinicalsupply

CROs: Need deeper scientific expertise for complex trials? Signant’s 50+ full-time clinical experts support CRO study teams on everything from protocol design to COA selection, data quality monitoring, and more– across every indication. See how we strengthen CRO partnerships → https://hubs.li/Q03RwmtH0 #clinicaltrials #CRO #science

🕸️Creepy tales from clinical trials past - and how Signant’s trial-tested, comprehensive solutions save study teams from these horrors 😱 https://hubs.li/Q03QXWg30 #ClinicalTrials #HappyHalloween 

We're pleased to announce that Dr. John Harrison has joined Signant Health as Clinical Vice President to advance our capabilities in neuroscience clinical trials. For sponsors developing treatments for Alzheimer's disease and CNS conditions, cognitive endpoints are increasingly critical to regulatory success. John brings 25+ years of experience helping sponsors integrate cognitive testing into drug development programs. His expertise positions Signant to continue to deliver comprehensive scientific support for neuroscience drug development programs from trial design through regulatory submission. Read the full announcement: https://hubs.li/Q03QV_hd0 #ClinicalTrials #Neuroscience #AlzheimersResearch #DrugDevelopment #CognitiveAssessment